Corporate Satellite Symposia and Education Theater Schedule
Schedule is subject to change. Times are listed in Central Time (CST).
Wednesday, May 10
11:00 AM-12:00 PM
The Bedrock of Personalized NF1 Care: Fundamental Principles of Managing NF1-Associated PNs and Other Tumors With Innovative Targeted Therapy
CME Morning Symposium (Oncology Topic)
This conversational exchange of ideas within a serial, case-based format will provide learners with an expert review of current recommendations and updated criteria for the diagnosis of NF1 and NF1-associated tumors, as well as insights on the pivotal shortcomings of conventional treatment approaches and the burgeoning emergence of novel targeted therapeutics, most notably MEK inhibitors, that are laying a new foundation for the management of NF1-related PNs and other tumors. The ‘Clinical Consults’ case discussion will seamlessly link to a mini-lecture on the evidence supporting the panel’s treatment choices in order to effectively guide the learner’s ability to translate current evidence into routine clinical practice.
Co-Chair and Presenter: Carlos G. Romo, MD; Johns Hopkins University
Co-Chair and Presenter: Laura Klesse, MD PhD; UT Southwestern Medical Center
This CME Corporate Forum Satellite Symposium is organized by PeerView Institute for Medical Education, supported by Alexion Pharmaceuticals, Inc.
11:00 AM-12:00 PM
Moving Towards a New Treatment Standard in Von Willebrand Disease
Non-CME Morning Symposium (Hematology Topic)
Von Willebrand disease is the most common inherited bleeding disorder, yet its diagnosis remains difficult owing to heterogeneity of signs and symptoms and laboratory testing that may not provide an accurate diagnosis. Therefore, a focused program on von Willebrand disease is desirable, especially for fellows and junior faculty.
Dr. Veronica Flood
Dr. Fernando Corrales
Robert Sidonio, Jr., MD MSc.; Emory University/Children's Healthcare of Atlanta
This non-CME symposium is supported by Octapharma.
A New Approach for Reducing the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients 1 Month of Age and older, with Localized Non-Metastic Solid Tumors
Non-CME Evening Symposium (Oncology Topic)
The goal of this program is to introduce the new FDA-approved medication PEDMARK, indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastic sold tumors. Content will include a discussion of related clinical trials, dosing and administration, and safety.
Noah Federman, MD; UCLA
This non-CME symposium is supported by Fennec Pharmaceuticals.
Thursday, May 11
Building a Foundation for Enhanced Outcomes in Pediatric ALL: Guidance on the Asparaginase Component of Modern Therapy
CME Afternoon Symposium (Hematology Topic)
This initiative will offer learners expert guidance on the skills and strategic thinking that inform the use of asparaginase therapy—while addressing real-world barriers to effective care (such as hypersensitivity/silent inactivation and asparaginase discontinuation, among others). Each Clinical Consult segment will pair a concise pediatric case scenario with a ‘mini-lecture.’
Co-Chair and Presenter: Luke Maese, DO; University of Utah/Primary Children's Hospital
Co-Chair and Presenter: Rachel Rau, MD; Texas Children's Cancer and Hematology Center
This CME Corporate Forum Satellite Symposium is organized by PeerView Institute for Medical Education, supported by Jazz Pharmaceuticals.
Hodgkin Lymphoma: New and Emerging Treatment Options for Pediatric and AYA Patients
CME Evening Symposium (Hematology Topic)
CME-certified live satellite symposium featuring expert panel discussion and case presentations designed to provide insights into new and emerging treatment options for children, adolescents, and young adults with hodgkin lymphoma. Questions and cases from the audience are encouraged and reinforce best practices and clinical application.
Program Director: Kara M. Kelly, MD; Roswell Park Comprehensive Cancer Center
Faculty: Lisa G. Roth, MD; Weill Cornell Medicine
This CME symposium is provided by Clinical Care Options, LLC. Supported by an educational grant from Seagen.
Friday, May 12
Solve the Case: When Splenomegaly in Children is Not Malignancy
Non-CME Morning Symposium (Hematology Topic)
This case-based presentation of Gaucher disease and ASMD will focus on the clinical features of these two lysosomal storage disorders that may present in a pediatric hematology setting. This presentation will also review the diagnostic process for Gaucher disease and ASMD as well as discuss a multi-disciplinary approach to management.
Caroline Hastings, MD & Can Ficicioglu, MD PhD
This non-CME symposium is supported by Sanofi.
The Chronic Neutropenia Conundrum: Diagnostic Challenges and Phenotypic Presentations of WHIM Syndrome
The goal of this program is to educate on WHIM Syndrome, the diagnostic challenges, phenotypic features, clinical presentation, and the role of genetic testing.
Susan E. Kirk, MSPAS PA-C, Baylor College of Medicine, Texas Children's Hospital
This education theater is supported by X4 Pharmaceuticals.
A Pediatric Case of Neurofibromatosis Type 1 (NF1) With Symptomatic, Inoperable Plexiform Neurofibromas (PN)
A physician-led case-based discussion with a specialist in neurofibromatosis type 1 (NF1). Maria Velez, MD, a nationally recognized pediatric hematologist oncologist and pediatrician at the Louisiana Cancer Research Center, will present a case of a pediatric NF1 patient with symptomatic, inoperable plexiform neurofibromas (PN). This is an Alexion-sponsored event.
Maria Velez, MD; LSU/Children's Hospital of New Orleans
This education theater is supported by Alexion.
The only FDA-approved Erwinia asparaginase for the treatment of ALL/LBL
Scott Howard, MD MSc; University of Tennessee Health Science Center
This education theater is supported by Jazz Pharmaceuticals Inc.
A Discussion on a Treatment Option for Sickle Cell Disease
Please join us for a discussion of the pathology of red blood cell sickling and how this may lead to subsequent anemia and hemolysis. We will also review the clinical efficacy and safety of a prescription treatment option for sickle cell disease.
Richard Drachtman, MD
This education theater is supported by Pfizer Inc.